Study of BTK Inhibitor, Ibrutinib in Combination With Carfilzomib in Subjects With Relapsed and Refractory Multiple Myeloma

ClinicalTrials.gov ID: NCT01962792

Public ClinicalTrials.gov record NCT01962792. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Oct 28, 2026, 10:54 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Multicenter Phase 1/2b Study of the Bruton's Tyrosine Kinase Inhibitor, Ibrutinib (PCI-32765), in Combination With Carfilzomib (Kyprolis™) in Subjects With Relapsed or Relapsed and Refractory Multiple Myeloma

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

A MULTICENTER PHASE 1/2B STUDY OF THE BRUTON'S TYROSINE KINASE INHIBITOR, IBRUTINIB (PCI-32765), IN COMBINATION WITH CARFILZOMIB (KYPROLIS™) IN SUBJECTS WITH RELAPSED OR RELAPSED AND REFRACTORY MULTIPLE MYELOMA

Study identification

NCT ID: NCT01962792
Recruitment status: Completed
Study type: Interventional
Phase: Phase 1, Phase 2
Lead sponsor: Pharmacyclics LLC.; Industry
Enrollment: 84 participants

Conditions and interventions

Conditions

Multiple Myeloma

Interventions

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Dec 2013 (Actual)
Primary completion: Mar 2019 (Actual)
Completion: Mar 2019 (Actual)
Last update posted: Dec 21, 2021

2013 – 2019

United States locations

U.S. sites: 16
U.S. states: 11
U.S. cities: 15

Facility	City	State	ZIP	Site status
City of Hope	Duarte	California	91010	—
University of California Los Angeles	Los Angeles	California	90095	—
Colorado Blood Cancer Institute	Denver	Colorado	80218	—
University of Nebraska Medical Center	Omaha	Nebraska	68198	—
New York Presbyterian Hospital - Weill-Cornell	New York	New York	10021	—
Mount Sinai Hospital	New York	New York	10029	—
Carolinas Healthcare System	Charlotte	North Carolina	28204	—
Duke University Medical Center	Durham	North Carolina	27705	—
University of Cincinnati	Cincinnati	Ohio	45267	—
Cleveland Clinic	Cleveland	Ohio	44195	—
Thomas Jefferson University	Philadelphia	Pennsylvania	19107	—
MUSC Hollings Cancer Center	Charleston	South Carolina	29425	—
Vanderbilt Ingram Cancer Center	Nashville	Tennessee	37232	—
University of Texas Southwestern Medical Center	Dallas	Texas	75390	—
Methodist Healthcare System	San Antonio	Texas	78229	—
Virginia Commonwealth University	Richmond	Virginia	23298	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 1 non-U.S. site.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT01962792, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Dec 21, 2021 · Synced Oct 28, 2026

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT01962792 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →